Abstract
ObjectiveOral squamous cell carcinoma (OSCC) is a prevalent cancer, especially in developing countries. Anthracyclines and their anthraquinone derivatives, such as doxorubicin, exhibit a cell growth inhibitory effect and have been used as anti-cancer drugs for many years. However, the cardiotoxicity of anthracycline antibiotics is a major concern in their clinical application. NSC745885 is a novel compound synthesized from 1,2-diaminoanthraquinone, which subsequently reacts with thionyl chloride and triethylamine. The present study aimed to investigate the anti-oral cancer potential and the safety of NSC745885.MethodsWe investigated the anti-cancer potential of NSC745885 in oral squamous carcinoma cell lines and in an in vivo oral cancer xenograft mouse model. The expression of apoptotic related genes were evaluated by real-time RT-PCR and western bloting, and the in vivo assessment of apoptotic marker were measured by immunohistochemical staining. The anti-tumor efficiency and safety between doxorubicin and NSC745885 were also compared.ResultsOur results demonstrated that NSC745885 exhibits anti-oral cancer activity through the induction of apoptosis in cancer cells and in tumor-bearing mice, and this treatment did not induce marked toxicity in experimental mice. This compound also exhibits a comparable anti-tumor efficiency and a higher safety in experimental mice when compared to doxorubicin.ConclusionsThe data of this study provide evidence for NSC745885 as a potential novel therapeutic drug for the treatment of human OSCC.
Highlights
Among oral squamous cell carcinomas (OSCCs), the greatest majority of malignancies are head and neck squamous cell carcinomas (HNSCCs)
We investigated the anti-cancer potential of NSC745885 in oral squamous carcinoma cell lines and in an in vivo oral cancer xenograft mouse model
Our results demonstrated that NSC745885 exhibits anti-oral cancer activity through the induction of apoptosis in cancer cells and in tumor-bearing mice, and this treatment did not induce marked toxicity in experimental mice
Summary
Among oral squamous cell carcinomas (OSCCs), the greatest majority of malignancies are head and neck squamous cell carcinomas (HNSCCs). OSCC is the sixth most prevalent cancer worldwide [1], and the third most common cancer in developing countries [2,3,4]. Traditional therapies for OSCC include surgery, radiotherapy, and chemotherapy. The remedial effect of such therapies on end-stage oral cancer is uniformly poor. Even after successful tumor resection, approximately 20% of patients may have recurrence of tumors at other site [5]. Developing novel therapeutic strategies for malignant oral tumors is an urgent issue
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
